StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $2.63 | $2.63 | +0.00% | 0.0M |
| 05-12 | $2.60 | $2.63 | +1.15% | 0.0M |
| 05-13 | $2.61 | $2.52 | -3.45% | 0.0M |
| 05-14 | $2.53 | $2.52 | -0.40% | 0.0M |
| 05-15 | $2.56 | $2.47 | -3.52% | 0.0M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
No sell-side coverage available for TCRT.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Fundamentals not available for TCRT.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $0.00 | $5.00K | $2.00K | $2.00K |
Operating Income | $-1.01M | $-4.22M | $-3.32M | $-2.13M |
Net Income | $-1.01M | $-4.18M | $-3.28M | $-2.12M |
EPS (Diluted) | $-0.59 | $-2.20 | $-1.84 | $-1.30 |
Total Assets | $1.88M | $2.97M | $3.72M | $4.74M |
Total Liabilities | $595.00K | $813.00K | $921.00K | $1.07M |
Cash & Equivalents | $354.00K | $1.39M | $1.94M | $2.88M |
Free Cash Flow OCF − CapEx | Not available | $-2.97M | $-2.41M | Not available |
Shares Outstanding | 2.38M | 2.35M | 2.21M | 2.07M |
Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.